The National Pediatric Alopecia Areata Registry in Russia: An Overview

The National Paediatric Alopecia Areata Registry in Russia included 92 patients aged 2 to 17 years, with 71 having at least one concomitant disease, most commonly atopic dermatitis. Half of the patients suffered from total hair loss. Among all patients, 23 children received off-label therapy with tofacitinib for a period of 16 ± 7.5 weeks. This therapy showed a positive effect in all patients with alopecia areata, with the SALT index decreasing significantly in 4 out of 6 patients and reaching 0 points in 2 patients. Furthermore, 32 of 46 patients with total and universal forms of alopecia improved their condition while taking tofacitinib. The study concludes that further research is needed on the features of alopecia areata and the efficacy and safety of systemic therapy in children.